Testosterone is essential for the prostate to grow in the first place, but giving testosterone to an adult man does not reliably make his prostate bigger in any clinically meaningful way. That disconnect surprises most people, because the relationship between testosterone and the prostate has been assumed to be straightforward for decades: more hormone, more growth. The reality involves a conversion step most people have never heard of, a “saturation” effect that limits how much the gland can respond, and a genuine paradox in which men with the lowest testosterone levels tend to have the largest prostates.
How Testosterone Reaches the Prostate
Testosterone circulating in the blood is not actually the primary androgen that acts on prostate tissue. When testosterone enters prostate cells, an enzyme called 5-alpha reductase converts it into dihydrotestosterone, or DHT. DHT binds the androgen receptor far more tightly than testosterone itself and is the form that drives prostate growth and maintenance.1PubMed Central. The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? This conversion happens mainly inside the prostate’s stromal cells, so what matters is not just how much testosterone is in the blood but how efficiently the tissue converts it.2PubMed Central. 5-alpha reductase inhibitors use in prostatic disease and beyond
During puberty, this pathway is what transforms the prostate from roughly the size of a rice kernel into its adult size. Androgens drive the entire process, and without them, the gland simply does not develop.3Journal of Family Medicine and Disease Prevention. Testosterone Effects on the Prostate Gland: Review of Pathophysiology and considerations in Prostate Cancer That observation, confirmed over and over, is the root of the assumption that testosterone is a direct prostate-growth signal at any age and at any dose. The assumption turns out to be far too simple.
What Testosterone Replacement Actually Does to Prostate Size
The strongest test of whether testosterone enlarges the prostate comes from studies of testosterone replacement therapy in men who are deficient. A systematic review and meta-analysis in European Urology pooled data from multiple randomized, placebo-controlled trials and found no significant changes in prostate volume, PSA levels, urinary symptom scores, or urine flow rates with either short-term or long-term testosterone replacement, regardless of whether it was given by injection, skin patch, or pill.4PubMed. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis In other words, bringing testosterone up to a normal range in men who were deficient did not make their prostates measurably bigger compared to placebo.
One longer-term retrospective study found a modest statistical signal: testosterone therapy was linked to an extra 0.22 mL per year of prostate growth compared to untreated periods.5Scandinavian Journal of Urology. Long-term effects of testosterone therapy on prostate volume and LUTS in hypogonadal men: a retrospective study To put that in context, the average adult prostate is around 20 to 30 mL, and it grows slowly with age in almost every man. An extra fifth of a milliliter per year is tiny, and in that same study, urinary symptoms, quality of life, and PSA levels did not significantly differ between treated and untreated periods.
A separate study that interrupted testosterone treatment midway through provided an interesting wrinkle: while men were on therapy their prostate volume increased, but when therapy was paused, the prostate kept growing anyway. Restarting therapy did not accelerate growth further.6PubMed Central. Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size The prostate was enlarging on its own timeline, largely independent of whether the man was receiving testosterone. That finding challenges the simple notion that testosterone is the throttle controlling prostate size in adulthood.
The Saturation Concept
One way researchers explain these findings is the idea that androgen receptors in the prostate become saturated at relatively low testosterone levels. Once enough testosterone (and the DHT it produces) is available to occupy most of those receptors, adding more hormone does not produce more growth. The prostate has already gotten what it needs.
A study of young men receiving graded testosterone doses illustrates this. At a moderate dose that kept testosterone near baseline levels, PSA barely budged. Even at the highest dose, which pushed testosterone levels roughly four times above normal, the PSA increase was small in absolute terms, rising from about 0.5 to 0.7 ng/mL.7PubMed Central. Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer That rise was statistically measurable, but it is far from the dramatic prostate response many would expect from quadrupling testosterone. The prostate simply does not respond proportionally to escalating doses. Below a certain threshold, testosterone matters enormously; above it, the effect flattens out.
The Low-Testosterone Paradox
If more testosterone meant a bigger prostate, you would expect men with naturally high levels to have the largest glands. The opposite appears to be true. In a study that followed men over four years, those with low testosterone had significantly larger prostates at baseline and experienced greater prostate growth over the follow-up period compared to men with normal testosterone.8Scientific Reports. Relationship between serum total testosterone and prostate volume in aging men Another study found that men with total testosterone below 4 ng/mL had roughly triple the odds of developing benign prostatic hyperplasia compared to men with higher levels.9PubMed. Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia
This is genuinely counterintuitive, and the explanation probably involves more than just testosterone itself. Low testosterone in aging men rarely exists in isolation. It tends to travel alongside insulin resistance, obesity, chronic inflammation, and hormonal shifts including a relative increase in estrogen. Each of those factors has its own pathway to prostate enlargement. In the research literature, this cluster is increasingly recognized as the metabolic connection to prostate growth, and it may matter more than testosterone levels themselves.
Metabolic Syndrome and Prostate Growth
Metabolic syndrome, the combination of insulin resistance, excess abdominal fat, high blood pressure, and abnormal cholesterol, has been linked to both larger prostate size and worse urinary symptoms. Clinical and experimental work has identified several molecular players connecting the two conditions, including insulin, insulin-like growth factor 1, estrogen, and inflammatory signaling molecules produced by fat tissue.10PubMed. Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection These factors can stimulate prostate cell growth and inflammation through pathways that have nothing to do with the androgen receptor.
Analysis from the large REDUCE trial found that men with higher insulin resistance had modestly larger prostates at every time point measured, though insulin resistance alone did not predict the rate of prostate growth over four years.11PubMed Central. Association between insulin resistance and prostate volume: A 4-year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial A separate study confirmed that after adjusting for age, insulin levels, inflammatory markers like C-reactive protein and TNF-alpha, and body-fat-related hormones like leptin and adiponectin were all significantly associated with prostate volume.12PubMed. The underlying mechanism of metabolic syndrome on benign prostatic hyperplasia and prostate volume
This is why the story about testosterone and the prostate is incomplete without talking about metabolism. A man with low testosterone, a large waist, and insulin resistance may have a bigger prostate than a lean man with normal testosterone, and the culprit is the metabolic environment rather than the hormone level itself.
Why Urinary Symptoms Often Improve on Testosterone
One of the more surprising findings in this area is that testosterone therapy frequently makes urinary symptoms better, not worse. A systematic review found that men with mild lower urinary tract symptoms who started testosterone either stayed the same or improved, and men with metabolic syndrome showed consistent improvement in urinary symptoms after treatment.13PubMed. The Relationship Between Testosterone-Replacement Therapy and Lower Urinary Tract Symptoms: A Systematic Review Multiple smaller trials and retrospective studies have pointed in the same direction.14PubMed Central. Testosterone and benign prostatic hyperplasia
How can the prostate grow slightly while symptoms get better? Size is only part of what causes urinary trouble. Bladder muscle function, inflammation within the prostate, smooth muscle tone in the urethra, and metabolic health all contribute. The study that paused and restarted testosterone therapy found that urinary symptom scores worsened when therapy was stopped and improved again when it resumed, even though prostate volume kept increasing either way.6PubMed Central. Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size Testosterone appears to help the bladder and lower urinary tract function more efficiently, and those functional improvements can outweigh any marginal tissue growth. Preliminary clinical trial results have also suggested that testosterone replacement may reduce inflammation within the prostate in men who have both low testosterone and metabolic syndrome.15Endocrine Abstracts. Testosterone replacement therapy is able to reduce prostate inflammation in men with BPH, metabolic syndrome and hypogonadism: preliminary results from a randomized placebo-controlled clinical trial
What About Supraphysiological Doses
The reassuring data above applies to men receiving normal replacement doses. The picture changes at extreme levels. A case report of a man who self-administered anabolic steroids at doses far above the therapeutic range documented increases in prostate volume, decreased urine flow, and increased nighttime urination during the period of steroid use.16Wiley Online Library / PubMed Central. Steroid abuse in athletes, prostatic enlargement and bladder outflow obstruction–is there a relationship? Case reports are limited evidence, but they suggest that pushing androgen levels well beyond the normal range can overwhelm the saturation ceiling, at least temporarily. If you are taking anabolic steroids for performance enhancement, the risks to the prostate are different from those of medically supervised testosterone replacement.
Blocking the Conversion Instead of the Hormone
The fact that DHT, not testosterone itself, is the primary growth signal in the prostate is the basis for a widely used class of drugs: 5-alpha reductase inhibitors. By blocking the enzyme that converts testosterone to DHT inside prostate cells, these medications reduce DHT levels without reducing testosterone. Compounds used in BPH and prostate cancer prevention have been shown to shrink the prostate substantially and cause visible atrophic changes in both benign and cancerous tissue.17Urology. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate These drugs are a standard part of care for men with enlarged prostates causing urinary problems.18PubMed Central. Androgens and estrogens in benign prostatic hyperplasia: past, present and future
The success of these drugs reinforces the point that it is the local hormonal environment inside the prostate, not the circulating testosterone level, that governs gland size. A man can have perfectly normal testosterone in his blood and still have his prostate shrink dramatically if the conversion to DHT is blocked.
Testosterone After Prostate Cancer Treatment
For decades, testosterone therapy was considered absolutely off-limits for any man who had been treated for prostate cancer. This fear traces back to the mid-twentieth century, when Charles Huggins demonstrated that testosterone stimulated prostate cancer activity and that removing the testes caused tumors to regress, work that earned him the Nobel Prize.19PubMed. Charles Brenton Huggins: A historical review of the Nobel laureate’s pioneering discoveries That finding was real and remains the foundation of androgen deprivation therapy, which is still used to slow advanced prostate cancer.
But the blanket ban on testosterone for all prostate cancer survivors has weakened as evidence has accumulated. A meta-analysis found that testosterone replacement, regardless of delivery method, was not associated with a statistically significant increase in prostate cancer development or progression in the short term.20Prostate Cancer and Prostatic Diseases. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis A systematic review of observational studies in men treated for localized prostate cancer found biochemical recurrence rates ranging from 0% to 7% after surgery and 0% to 6% after radiation therapy, with up to five years of follow-up.21PubMed. Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies In several studies, recurrence rates in men on testosterone were actually lower than in untreated comparison groups.22International Journal of Impotence Research. Testosterone replacement therapy following definitive treatment for prostate cancer: a scoping review of safety and efficacy
This does not mean testosterone is protective against cancer recurrence. The men receiving testosterone in these studies were carefully selected, closely monitored, and typically had low-risk or intermediate-risk disease. The takeaway is more modest: in the right patient with proper surveillance, testosterone replacement after prostate cancer treatment does not appear to fuel regrowth of the cancer. Researchers who have studied this in men after robotic prostatectomy have described it as oncologically safe in well-selected, closely followed patients.23PubMed. Oncological safety and functional outcomes of testosterone replacement therapy in symptomatic adult-onset hypogonadal prostate cancer patients following robot-assisted radical prostatectomy Long-term randomized data are still needed.
The Role of the Androgen Receptor Itself
Not everyone’s prostate responds to the same testosterone level in the same way, and genetics play a role. The androgen receptor gene contains a variable stretch of repeating DNA. Men with shorter repeat lengths have receptors that are more transcriptionally active, meaning their prostate cells respond more strongly to a given amount of DHT. Shorter repeat lengths have been associated with a higher risk of prostate cancer.24PubMed. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia This is a reminder that the question “does testosterone grow the prostate” has a different practical answer for different men, even at the same hormone levels. The receptor’s sensitivity varies, and that variation modifies individual risk.
Why Dogs Get It Too
Humans are not the only species that develop enlarged prostates with age. Dogs do as well, and in both species, benign prostatic hyperplasia occurs only in males with functioning testes.25The American Journal of Medicine. The pathogenesis of benign prostatic hyperplasia This makes dogs the preferred animal model for studying the condition and testing potential treatments.26PubMed Central. Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms Most other mammals do not develop BPH naturally. The shared vulnerability between humans and dogs appears to be connected to the combination of long lifespans and a hormonal environment that shifts with age, including the ratio of androgens to estrogens. Neutered dogs rarely develop prostate enlargement, just as castrated men do not, which reinforces that a functioning androgen supply is a prerequisite for the condition even if the dose-response relationship above the baseline threshold is weak.